TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3323512

Group type: EXPERIMENTAL
Intervention: Urethral catheter removal in the early morning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Urethral catheter removal in the late night
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients presenting with acute urinary retention
Number of subjects: 0
Study: 30124473

Group type: EXPERIMENTAL
Intervention: Prednisone initiated alongside ART in selected patients with CD4 less than 100 cells/μl
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early ART initiation in TB patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ART
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 0
Study: 26702772

Group type: EXPERIMENTAL
Intervention: XELOX (capecitabine, oxaliplatin)
Number of subjects: 441

Group type: COMPARATOR
Intervention: modified FOLFOX6 (5‐fluorouracil, leucovorin, oxaliplatin)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: CIMP(+) tumors
Number of subjects: 441
Study: 24152889

Group type: EXPERIMENTAL
Intervention: Ferrous bisglycinate 25 mg iron/day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ferrous sulfate 50 mg iron/day
Number of subjects: 80
Study: 22418243

Group type: EXPERIMENTAL
Intervention: Cisplatin (50mg/m(2)) on days 1, 8, 29, and 36 and etoposide (50 mg/m(2)) on days 1‐5 and 29‐33 plus 60 Gy of thoracic radiotherapy (TRT)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Weekly concurrent carboplatin (AUC = 2) and paclitaxel (45 mg/m(2)) plus 60 Gy of thoracic radiotherapy (TRT)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Cisplatin/etoposide (PE) regimen
Number of subjects: 65

Group type: COMPARATOR
Intervention: Paclitaxel/carboplatin (PC) regimen
Number of subjects: 65
Study: 20145553

Group type: EXPERIMENTAL
Intervention: Video + cues
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Verbal-only
Number of subjects: 9

Group type: COMPARATOR
Intervention: Video-only
Number of subjects: 9
Study: 19218664

Group type: EXPERIMENTAL
Intervention: C-Flex
Number of subjects: 30

Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 30
Study: 15998425

Group type: EXPERIMENTAL
Intervention: Non-interferon-based therapy (N-IFN-BT) - ribavirin (600-800 mg) + amantadine (200 mg) + ursodeoxycholic acid (UDCA) (500 mg) for 24 weeks
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Non-interferon-based therapy (N-IFN-BT)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Silymarin therapy - 450 mg/day for 24 weeks
Number of subjects: 170
Study: 12531669

Group type: EXPERIMENTAL
Intervention: lightweight removable wrist splint
Number of subjects: 66

Group type: COMPARATOR
Intervention: plaster cast
Number of subjects: 66
Study: 10386713

Group type: EXPERIMENTAL
Intervention: Late course accelerated hyperfractionated (LCAF) group
Number of subjects: 85

Group type: COMPARATOR
Intervention: Conventional fractionation (CF) group
Number of subjects: 85
Study: 8886216

Group type: EXPERIMENTAL
Intervention: Naprelan 500 mg
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Naprelan 1000 mg
Number of subjects: 129

Group type: COMPARATOR
Intervention: Naproxen 500 mg
Number of subjects: 129

Group type: COMPARATOR
Intervention: Codeine 30 mg
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Naprelan (both doses)
Number of subjects: 129
Study: 1878587

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 1,200 mg/d, 1,600 mg/d, and 2,000 mg/d from day -10 through day +100 posttransplant
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX)
Number of subjects: 30
Study: 29072852

Group type: EXPERIMENTAL
Intervention: Mepitel Film
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sorbolene cream (NZ) or Biafine cream (China)
Number of subjects: 36
Study: 27134249

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) monotherapy
Number of subjects: 474

Group type: COMPARATOR
Intervention: Etanercept (ETN) with Methotrexate (MTX)
Number of subjects: 474
Study: 24373927

Group type: EXPERIMENTAL
Intervention: Hs-CRP (0) - freshly collected sample
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hs-CRP (LT) - samples stored at -80°C for 7-11 years
Number of subjects: 30
Study: 22775078

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept 4 mg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Intravitreal aflibercept 0.15 mg
Number of subjects: 28
Study: 20151792

Group type: EXPERIMENTAL
Intervention: Estradiol (E2) 1 mg/day + norethisterone acetate (NETA) 0.5 mg/day for 2 months, followed by placebo for 4 months
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Estradiol (E2) 1 mg/day + norethisterone acetate (NETA) 0.5 mg/day for 4 months, followed by placebo for 2 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 60
Study: 18330483

Group type: EXPERIMENTAL
Intervention: Oxybutynin
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Functional electrostimulation (FES)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Pelvic floor training (PFT)
Number of subjects: 64
Study: 17141704

Group type: EXPERIMENTAL
Intervention: Intervention group (microfinance and training curriculum)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (comparison group)
Number of subjects: 8
Study: 12697871

Group type: EXPERIMENTAL
Intervention: Three 72-hour infusions of carmustine (BiCNU) and cisplatin followed by radiation therapy
Number of subjects: 219

Group type: COMPARATOR
Intervention: Radiation therapy with standard adjuvant BiCNU
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Experimental arm (carmustine and cisplatin)
Number of subjects: 219
Study: 11030166

Group type: EXPERIMENTAL
Intervention: Two plasma exchanges (PE)
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: Four plasma exchanges (PE)
Number of subjects: 556
Study: 9772542

Group type: EXPERIMENTAL
Intervention: PGE1
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (N. S.)
Number of subjects: 20
Study: 7902369

Group type: EXPERIMENTAL
Intervention: Low dose of naltrexone
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: High dose of naltrexone
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 2994500

Group type: EXPERIMENTAL
Intervention: Schedule A (once daily by rapid infusion)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Schedule B (continuous 24 hr infusion)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Schedule C (divided doses every eight hours by rapid infusion)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Standard treatment (STD)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Groups B + C (combined)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Groups A + STD (combined)
Number of subjects: 55
Study: 31128958

Group type: EXPERIMENTAL
Intervention: Educational intervention targeting physicians (intensive 2-day training workshop, educational outreach visits, mobile health application)
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Educational intervention targeting physicians
Number of subjects: 357

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 357
Study: 29314355

Group type: EXPERIMENTAL
Intervention: Consultation with oncology social workers (OSWs)
Number of subjects: 226
Study: 27227568

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic fields (PEMFs) at 0.5 mT, 12 Hz, for 30 minutes
Number of subjects: 43

Group type: COMPARATOR
Intervention: Sham PEMFs
Number of subjects: 43
Study: 24497796

Group type: COMPARATOR
Intervention: CT-guided sclerotherapy without ethanol concentration monitoring (group A)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: CT-guided sclerotherapy with ethanol concentration monitoring (group B)
Number of subjects: 67
Study: 23364033

Group type: EXPERIMENTAL
Intervention: Passive upper arm exercise for 30 minutes per session, twice a day for 2 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 50
Study: 20008966

Group type: EXPERIMENTAL
Intervention: Proscriptive orientation priming
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prescriptive orientation priming
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transgressions representing proscriptive violations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transgressions representing prescriptive violations
Number of subjects: 0
Study: 18534554

Group type: EXPERIMENTAL
Intervention: High-intensity exercise (body weight-supported treadmill training)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low-intensity exercise
Number of subjects: 30

Group type: COMPARATOR
Intervention: Zero-intensity education group
Number of subjects: 30
Study: 15940046

Group type: EXPERIMENTAL
Intervention: Low-dose dopamine (LDD) infusion over the second 3-hr period
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low-dose dopamine (LDD) infusion over both the first and third 3-hr periods
Number of subjects: 20
Study: 11899820

Group type: EXPERIMENTAL
Intervention: Amixin
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Cycloferon
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo (Group 1a and 2a)
Number of subjects: 113
Study: 10412886

Group type: EXPERIMENTAL
Intervention: 1.5 g of paracetamol orally
Number of subjects: 50
Study: 8590154

Group type: EXPERIMENTAL
Intervention: Oral supplement of 1000 IU/day vitamin D for 1 year
Number of subjects: 75

Group type: COMPARATOR
Intervention: No supplement
Number of subjects: 75
Study: 2188314

Group type: EXPERIMENTAL
Intervention: Flurbiprofen, a topically applied nonsteroidal anti-inflammatory agent, preoperatively administered.
Number of subjects: 99
Study: 7002479

Group type: EXPERIMENTAL
Intervention: Glucosamine sulphate (250 mg, 3 times daily for 6 to 8 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (2 capsules, 3 times daily for 6 to 8 weeks)
Number of subjects: 20
Study: 30970655

Group type: EXPERIMENTAL
Intervention: Armeo Spring robot-assisted trainer (n = 17)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Kinect-based system (n = 25)
Number of subjects: 42
Study: 28595498

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 2704

Group type: EXPERIMENTAL
Intervention: Active smoking
Number of subjects: 2704

Group type: EXPERIMENTAL
Intervention: Male former smokers
Number of subjects: 2704
Study: 26224692

Group type: EXPERIMENTAL
Intervention: Culture-directed antibiotic therapy for 2 weeks
Number of subjects: 8
Study: 23839583

Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT) with alglucosidase alfa
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (HMV alone)
Number of subjects: 14
Study: 21647724

Group type: EXPERIMENTAL
Intervention: 6-week school-based back education programme (predominantly biomechanically oriented) implemented by a physical therapist
Number of subjects: 194

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 194
Study: 19792837

Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl spray (INFS)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Oral transmucosal fentanyl citrate (OTFC)
Number of subjects: 139
Study: 16888272

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 0
Study: 14611914

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy after complete resection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postoperative treatments (chemotherapy, radiotherapy or both)
Number of subjects: 0
Study: 11074215

Group type: EXPERIMENTAL
Intervention: Enhanced external counterpulsation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intra-aortic balloon pumping
Number of subjects: 0
Study: 8844019

Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF) at doses of 50, 125, or 250 micrograms/m2 daily by subcutaneous self-injection for 28 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 12
Study: 1636624

Group type: EXPERIMENTAL
Intervention: Glyburide with fish oil (8 g/d)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Glyburide alone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Glyburide with fish oil
Number of subjects: 10
Study: 2936285

Group type: EXPERIMENTAL
Intervention: 0.10 mg . kg‐1 atracurium dibesylate
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 0.15 mg . kg‐1 atracurium dibesylate
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 0.20 mg . kg‐1 atracurium dibesylate
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 0.30 mg . kg‐1 atracurium dibesylate
Number of subjects: 35
Study: 31296491

Group type: EXPERIMENTAL
Intervention: NBTXR3 plus radiotherapy
Number of subjects: 176

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 176
Study: 29557754

Group type: EXPERIMENTAL
Intervention: AC+AN+HL ointment mixture (Group A, N=21)
Number of subjects: 41

Group type: COMPARATOR
Intervention: AC ointment alone (Group B, N=20)
Number of subjects: 41
Study: 26032635

Group type: EXPERIMENTAL
Intervention: AFXL pretreatment + AHES
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: AFXL pretreatment + EMLA cream
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham AFXL + AHES
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham AFXL + EMLA cream
Number of subjects: 10
Study: 24796381

Group type: EXPERIMENTAL
Intervention: Reasons for limiting drinking (social reasons)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Reasons for limiting drinking (lifestyle reasons)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Reasons for limiting drinking (impairment concerns)
Number of subjects: 254
Study: 22349562

Group type: EXPERIMENTAL
Intervention: Holding a long baton
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Holding a short baton
Number of subjects: 0

Group type: COMPARATOR
Intervention: No baton
Number of subjects: 0
Study: 19837180

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 17589284

Group type: EXPERIMENTAL
Intervention: Community-based collaborative peer advisor/advanced practice nurse intervention
Number of subjects: 247

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 247
Study: 15960427

Group type: EXPERIMENTAL
Intervention: PMBL (Polivalent Mechanical Bacterial Lysate) - 1 tablet a day for the first ten days during three consecutive months.
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: CLBL (oral immunostimulating lysate) - 1 capsule a day for the first ten days during three consecutive months.
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control NT - no immunostimulating treatment.
Number of subjects: 114
Study: 12010356

Group type: EXPERIMENTAL
Intervention: Ritonavir (RTV) 100-400 mg
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Saquinavir (SQV) 400-1800 mg
Number of subjects: 97
Study: 10515817

Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccines (3 experimental vaccines containing 6B and 19F)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccines (2 experimental vaccines)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccines (1 experimental vaccine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation between opsonophagocytic titers and IgG antibody levels by ELISA
Number of subjects: 0
Study: 7743989

Group type: EXPERIMENTAL
Intervention: Standard ORS (100 ml/kg)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Rice-based ORS (100 ml/kg)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Breast-feeding (absence)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Non-breast-fed children
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Low weight-for-height
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Moderate or severe dehydration
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Low plasma specific gravity or total plasma protein
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Longer duration of diarrhoea before inclusion
Number of subjects: 150
Study: 2337005

Group type: EXPERIMENTAL
Intervention: Geriatric consultation team (GCT) intervention with follow-up after discharge
Number of subjects: 132
Study: 430238

Group type: EXPERIMENTAL
Intervention: 36 g nitrogen per day
Number of subjects: 6

Group type: COMPARATOR
Intervention: 12 g nitrogen per day
Number of subjects: 6
Study: 30840141

Group type: EXPERIMENTAL
Intervention: EXCIMER laser-assisted trephination
Number of subjects: 68

Group type: COMPARATOR
Intervention: FEMTO laser-assisted trephination
Number of subjects: 68
Study: 28899589

Group type: EXPERIMENTAL
Intervention: Flexor Carpi Radialis (FCR) tendon
Number of subjects: 60

Group type: COMPARATOR
Intervention: Allograft
Number of subjects: 60
Study: 26277887

Group type: EXPERIMENTAL
Intervention: pioglitazone 15 mg once daily
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: pioglitazone 30 mg once daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: alogliptin 25 mg once daily (control)
Number of subjects: 100
Study: 22832022

Group type: EXPERIMENTAL
Intervention: system support
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: list support
Number of subjects: 60

Group type: COMPARATOR
Intervention: no memory support
Number of subjects: 60
Study: 21775563

Group type: EXPERIMENTAL
Intervention: Fish oil (2.7 g long-chain n-3 fatty acids daily during the third trimester)
Number of subjects: 533

Group type: COMPARATOR
Intervention: Olive oil (control group)
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Biochemical measures (insulin, glucose, glycated hemoglobin, leptin, adiponectin, insulin-like growth factor I, high-sensitivity C-reactive protein)
Number of subjects: 533
Study: 19957549

Group type: EXPERIMENTAL
Intervention: Goserelin 3.6 mg once every 4 weeks for 12 weeks (Group A)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Goserelin with 1/2 piece of estradiol patch weekly and 6 mg oral medroxyprogesterone acetate daily for 12 weeks (Group B)
Number of subjects: 28
Study: 17604961

Group type: EXPERIMENTAL
Intervention: Tissue Doppler echocardiography/SR imaging at rest and during bicycle exercise at 1 and 2 W/kg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 24
Study: 15386934

Group type: EXPERIMENTAL
Intervention: G‐Hesperidin at 100 or 500 mg/d for 6 weeks
Number of subjects: 0
Study: 11496020

Group type: EXPERIMENTAL
Intervention: Fluoxetine (6 weeks open-label treatment followed by 6 weeks double-blind treatment)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (6 weeks double-blind treatment)
Number of subjects: 15
Study: 9771234

Group type: EXPERIMENTAL
Intervention: Non-latex surgical gloves
Number of subjects: 4

Group type: COMPARATOR
Intervention: Latex surgical gloves
Number of subjects: 4
Study: 7796388

Group type: EXPERIMENTAL
Intervention: Lysosomal arylsulphatase A activity in leukocytes from patients with acute leukemia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 0
Study: 2205182

Group type: EXPERIMENTAL
Intervention: 0.5% topical apraclonidine hydrochloride
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.25% topical apraclonidine hydrochloride
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.5% timolol maleate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (implied control)
Number of subjects: 20
Study: 71971

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 150 mg twice daily (morning and evening) plus placebo at mid-day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Flurbiprofen 100 mg three times daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (both regimens)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Flurbiprofen 150 mg twice daily
Number of subjects: 30
Study: 31590930

Group type: EXPERIMENTAL
Intervention: SDAI remission
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CDAI remission
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DAS28(CRP) remission
Number of subjects: 0

Group type: COMPARATOR
Intervention: SDAI or CDAI remission but not Boolean remission
Number of subjects: 0

Group type: COMPARATOR
Intervention: DAS28(CRP) remission but not Boolean remission
Number of subjects: 0
Study: 31135088

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: incobotulinumtoxinA
Number of subjects: 30
Study: 27712924

Group type: EXPERIMENTAL
Intervention: Testosterone administration for 48h
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 26424549

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy intensification plus HIV DNA prime and rAd5 boost vaccine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Antiretroviral therapy intensification alone
Number of subjects: 28
Study: 23625478

Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 22174164

Group type: EXPERIMENTAL
Intervention: 50,000 IU vitamin D3
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: 100,000 IU vitamin D3
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (vitamin E)
Number of subjects: 102
Study: 18824930

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cycling ergometry (CYL)
Number of subjects: 20
Study: 15897791

Group type: EXPERIMENTAL
Intervention: EDUC + FPI
Number of subjects: 61

Group type: COMPARATOR
Intervention: EDUC
Number of subjects: 61
Study: 12849767

Group type: EXPERIMENTAL
Intervention: Continuous rapid naming tasks (digit and color naming)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Balancing problems (assessed singly and with a secondary task)
Number of subjects: 40
Study: 10199338

Group type: EXPERIMENTAL
Intervention: Gabapentin (400 mg 3 times daily)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg 3 times daily)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 7710444

Group type: COMPARATOR
Intervention: 0.5-20 mg intravenous pancopride
Number of subjects: 40

Group type: COMPARATOR
Intervention: 5-40 mg oral solution of pancopride
Number of subjects: 40

Group type: COMPARATOR
Intervention: 20 mg intravenous infusion, oral tablet and oral solution
Number of subjects: 40
Study: 1693030

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 22

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 22
Study: 7008978

Group type: EXPERIMENTAL
Intervention: Topical benzydamine (10/00)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124